Whatever the reason or scientific explanation may be, topical application of the active ingredient and compositions of the present invention has produced remarkably good elfects in female patients with diffuse hairfall or thinning out of the female pattern alopecia type (alopecia androgenetica)
In men with male pattern alopecia, results have been much less spectacular, but still sufficiently successful to warrant continuation of the treatment over a period of several years.
As already noted, the various side effects which commonly appear in patients treated with estrogens did not appear when using the active ingredient and compositions of the invention in the manner of the present invention. It thus appears that one can actually speak of a separated hormonal activity in the sense that the active ingredient is active at the site of topical application for purposes of the present invention, but produces, as far as has been observed to date, no systemic effects on the internal sexual organs upon resorption.
in persons with a strong hereditary trend to abnormal sensitivity or reactivity of the hair follicles in certain areas of the scalp to androgen, particularly to testosterone, must be expected to respond much more slightly if at all to any treatment, and such is the observed fact when employing the treatment and compositions of the present invention. Thus, only in men with a weaker trend to baldness can any observable reduction in hairfall and/or the resulting thinning out of the hair be expected. In women, where the trend toward baldness because of the female hormone balance is much less, the observable effect is much greater and occurs more frequently.
The activity of estrogen in evoking a marked increase in the activity of several amino acid-activating enzymes, which are involved in the biosynthesis of protein, and thus also with hair growth phenomenon, may be a factor.
The active ingredient of the invention, as previously stated, is estriol. The compositions of the invention involve the active ingredient in a pharmaceutically and cosmetically acceptable solvent, which comprises at least mainly if not entirely volatile components, such as lower alcohols, preferably ethyl or isopropyl alcohol or a mixture thereof, preferably diluted with water. In such composition, the water is a less volatile, but still slowly evaporating component.
The concentration of the active ingredient in the solution or suspension should be at least 0.02 percent, is preferably at least 0.05 percent, and has a maximum useful upper limit of approximately 0.2 percent. Higher percentages up to about 1 percent may be used if desired but are not economically attractive. Striking results have been obtained at about 0.1 percent or slightly above, but treatment effects can sometimes be increased by increasing the concentration of the active ingredient in the compositions of the invention.
METHOD OF TREATING The treatment of the invention is carried out by applying the active ingredient in any acceptable form, advantageously in a pharmaceutically and cosmetically acceptable topical solvent, and preferably in the form of a composition according to the present invention, to the scalp subject to the undesirable condition, preferably once a day. The recommended period of treatment is at least six months before a preliminary assessment of the results can be made. If no obvious hairfall is present, most male patients will require from eight to twelve months of treatment or even more before satisfactory observable results are obtained. The minimum period of treatment before favorable results have been positively effected has been approximately twelve weeks.
In any event, the recommended treatment is application to the parts of the hair and/or scalp having the undesirable condition, preferably at least once daily, and the recommended period of treatment before definite assessment of positive effect is at least six months. For
maximum efiicacy a year or more is usually recommended, particularly for men.
Example 1 The composition most commonly used in the clinical experiments reported herein is designated Composition 0L and has the following formula:
Estriol 0.1 gram. Benzalkonium chloride (antibacterial surface-active agent) 0.05 gram.
Ethyl alcohol 39.0 grams.
Corrigentia odor As desired.
Distilled water To make 100ml.
of solution.
Use of such a composition has been found entirely satisfactory. In many cases, application of approximately 50 ml. of the composition per week
the solubility of estriol in m1. of solvent is as follows: In 95% ethanol 1.2%
If an effective treatment can be given, it will, obviously, have to continue for several months, before the poorly functioning follicles will be restored to a degree, where thicker hairs with a close-to-normal life span can again be produced, and the telogen count (if increased) can reverse towards normal values. Therefore, when the possible efiicacy of a new treatment is studied, no definite evaluation can be undertaken until the lapse of a considerable time span.
Even patients who ultimately obtained an obvious improvement could sometimes see little effect in the first three or four months.
Summary of clinical results: Upon a recent survey of the clinical material, 122. patients had been treated and observed for a sufficiently long period (6 months or more) to allow estimation of the results.
In some cases, the total assessment was made only on the basis of such subjective estimation by the patient, his or her family and the hairdresser. In most cases, to this information was added a direct observation of the amount of hair in samples taken at regular intervals in connection with shampooing procedures, comparisons of photographs taken before and after the treatment, and different- Females Males Total Obviously very good, well verified improvement. 16 2 18 Good, but less obvious and less impressive improvement 21 22 43 Clearly positive 37 24 61 +1 Improvement observed, but not sufficiently clear or well documented to be classed as may get improved grade 12 7 19 after longer observation 7 Improvement so far questionable, but some of these cases may be classed as after longer observation 5 9 14 Negative or nearly negative result, or possibly slight improvement 13 28 Doubtful or negative 5 On this basis, the percentage improved was 50%.
Side effects: A boy of 1'8 observed swelling and slight tenderness of the mamillary area after three weeks treatment, disappearing again two weeks after stopping the treatment. When this had happened twice, further experiments were abstained from.
With this exception, during the trial period of five years no systemic side eflfects have been observed, that could reasonably be considered to have been caused by the treatment.
In men, the results have necessarily been less spectacular. However, a continuing hairfall has often decreased and a recently started thinning out of the hair has stopped in some cases. In several patients, the process appears to proceed more slowly under treatment. Also in On the basis, the percentage improved was 61/132: 46.21%.